Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1321-1326

  Tantiworawit, Adisak ^a,b   Power, Maryse M ^a,b   Barnett, Michael J ^a,b   Hogge, Donna E ^a,b   Nantel, Stephen H ^a,b   Nevill, Thomas J ^a,b   Shepherd, John D ^a,b   Song, Kevin W ^a,b   Sutherland, Heather J ^a,b   Toze, Cynthia L ^a,b   Abou Mourad, Yasser R ^a,b   Narayanan, Sujaatha ^a,b   Broady, Raewyn C ^a,b   Forrest, Donna L ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

CML; imatinib; Sudden blast phase

Indexed keywords

IMATINIB;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SOKAL SCORE; SUDDEN BLAST PHASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BLAST CRISIS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862728693     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.652108     Document Type: Article

References (21)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-1061.
2. Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006;107:480-482. (Pubitemid 43076368)
3. Alimena G, Breccia M, Latagliata R, et al. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006;107:1008-1013. (Pubitemid 44291150)
4. Kantarjian H, O'Brien S, Cortes J, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia:patterns and implications. Cancer 2003;98:81-85. (Pubitemid 36741129)
5. Kim A, Goldstein S, Luger S, et al. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia. Am J Clin Pathol 2008;129:639-648.
6. Ali R, Ozkalemkas F, Ozkocaman V, et al. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. Int J Clin Oncol 2009;14:545-550.
7. Avery S, Nadal E, Marin D, et al. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res 2004;28(Suppl. 1):S75-S77. (Pubitemid 38251503)
8. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003;40:62-68.
9. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107: 587-599.
10. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820. (Pubitemid 44394987)
11. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1998.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Hughes T, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosedchronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and ST1571 (IRIS). Blood 2010;116:3758-3765.
15. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008;112:837-845. (Pubitemid 351240578)
16. Jiang X, Forrest D, Nicolini F, et al. Properties of CD34+CML/stem/ progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 2010;116:2112-2121.
17. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
18. Kantarjian H, Shah N, Hochhaus A, et al. Dasatinib versus imantinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
19. Wadhwa J, Szydlo R, Apperley J, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002;99:2304-2309. (Pubitemid 34525413)
20. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-3553. (Pubitemid 34534521)
21. Wright M, Shepherd J, Barnett M, et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639-646.